#United Kingdom #Cryoablation #ProSense #Aberdeen #IceCure

IceCure's ProSense® at EUSOBI 2025

IceCure Medical recently participated in the European Society of Breast Imaging (EUSOBI) Congress 2025 held in Aberdeen, UK, showcasing its innovative ProSense® technology aimed at revolutionizing the treatment of early-stage breast cancer. The event, which took place from September 25-27, was a focal point for the latest advancements in the field, highlighting the growing trend towards less invasive treatment options through cryoablation.

Workshop Enthusiasm

The workshop titled "Unlocking De-Escalation of Care: Cryoablation for Breast Cancer", led by notable figures in the medical community, Dr. Federica Di Naro and Dr. Lucía Graña-Lopez, was met with an overwhelming response. Filled to capacity, the workshop demonstrated strong interest among professionals in exploring how ProSense® applies to current treatment protocols for breast cancer.

ProSense® is a pioneering system utilizing cryoablation to destroy tumors by freezing them, representing not only a change in methodology but also a significant advancement in patient care. IceCure's CEO, Eyal Shamir, emphasized how the approach addresses the need for more personalized treatments that prioritize patient outcomes and cosmetic results over radical surgical interventions.

Groundbreaking Studies Presented

During the congress, five independent studies focusing on the effectiveness of ProSense® were presented, indicating a robust foundation of clinical research supporting its adoption. Among the highlights:

• - Dr. Francesca Pugliese received the Young Physician-Scientist Grant for her research involving post-procedure imaging as a noninvasive biomarker, showcasing a promising avenue for treatment evaluation. Her work demonstrated a strong correlation between lesion conspicuity on contrast-enhanced mammography after cryoablation and positive tumor response, marking a significant step forward in monitoring treatment efficacy.

• - Further studies presented by Dr. Di Naro assessed the efficacy of percutaneous cryoablation compared to traditional hormone therapy. The results indicated that at 12 months post-treatment, the cryoablation group exhibited a complete response rate of 75.8%, significantly better than hormone therapy alone, positioning cryoablation as a reliable local treatment for elderly patients who may be unsuitable for surgery.

• - Another notable study examined non-surgical approaches for hormone receptor-positive breast cancer. The findings suggested that cryoablation combined with hormone therapy achieved an impressive tumor-free rate of 91.2%, providing compelling evidence for this dual approach and reinforcing the potential of cryoablation in managing hormone receptor-positive cases.

• - Preliminary outcomes from additional studies indicated that cryoablation remains a feasible and effective option for early-stage breast cancer, with no major complications reported and excellent cosmetic results noted by patients.

The Future of Breast Cancer Treatment

IceCure’s ProSense® offers a minimally invasive alternative to surgical tumor removal that aligns with global shifts in cancer treatment strategies towards more conservative and patient-friendly solutions. The success of the EUSOBI congress underscores an urgent need within the medical community to adapt to these cutting-edge techniques.

In summary, IceCure Medical’s ProSense® is not just an advancement in cryoablation technology; it signifies a transformative approach to breast cancer management that prioritizes effectiveness, safety, and patient experience. As awareness and research around cryoablation continues to grow, its adoption in clinical practice is likely to shape the landscape of breast cancer treatment for years to come.